- Lonza has signed an agreement to acquire Redberry SAS, a company specialising in rapid microbiology testing solutions using solid-phase cytometry (SPC) technology.
- The acquisition will enhance Lonza’s quality control capabilities and accelerate testing for pharmaceutical and biopharma manufacturers, with the transaction expected to close in Q4 2025.
Lonza, one of the world’s largest contract development and manufacturing organisations (CDMOs), has announced an agreement to acquire Redberry SAS, a French company specialising in rapid microbiology testing solutions based on solid-phase cytometry (SPC) technology.
Redberry’s Red One™ System delivers rapid sterility and bioburden testing designed to improve speed, sensitivity, and reliability in pharmaceutical quality control. The technology enables sterility results in four days, compared to the traditional 14-day incubation period required by conventional methods.
The acquisition will strengthen Lonza’s position in the global QC testing market, expanding its existing portfolio, which includes endotoxin detection and microbiological control services. Integrating Redberry’s Red One™ platform will allow Lonza to offer faster, automated testing solutions to its CDMO customers, particularly those producing short shelf-life biologics and cell and gene therapies.
“Our agreement to acquire Redberry marks a significant milestone in our commitment to advancing QC microbiology solutions in line with growing industry demand for rapid testing platforms. By integrating this cutting-edge technology into our portfolio, we are empowering customers with faster and simpler tools that lower compliance costs.”
Mike Goetter, Head of Bioscience, Specialized Modalities at Lonza
The transaction is expected to close in the fourth quarter of 2025, subject to closing conditions, and is not financially material to Lonza’s overall guidance.
